Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 07:00 ET | Source: Lifecore Biomedical, Inc.

Lifecore Biomedical Signs CDMO Master Services Agreement with New Large Multinational Pharmaceutical Customer

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product Partner’s Program Size Positions it to Become a Top Five...
December 16, 2025 07:00 ET | Source: Lifecore Biomedical, Inc.

Lifecore Biomedical to Participate at 44th Annual J.P. Morgan Healthcare Conference

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
December 15, 2025 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
December 12, 2025 09:59 ET | Source: Equity Insider

Healthcare AI Exits Pilot Phase, Enters Production Deployment

VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Healthcare organizations are setting the pace for enterprise AI adoption as operational automation...
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 02, 2025 12:13 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)

Quetzal Therapeutics Launches Phase III Clinical Trial of Oral QTX-2101 for Acute Promyelocytic Leukemia (APL)
December 01, 2025 09:17 ET | Source: MAIA Biotechnology, Inc.

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

CHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted...
December 01, 2025 02:00 ET | Source: Opterion Health AG

Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer

MUTTENZ, Switzerland, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a clinical-stage biopharmaceutical company pioneering innovation in peritoneal dialysis (PD), is pleased to announce the...
November 19, 2025 09:45 ET | Source: FN Media Group LLC

Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...
November 12, 2025 14:21 ET | Source: Quetzal Therapeutics

Quetzal Therapeutics Appoints Todd Smith as Board Member

Quetzal Therapeutics Appoints Todd Smith as Board Member